First Targeted Adjuvant Therapy for EGFR Non Small Cell Lung Cancer

2020-12-21T13:39:56-06:00December 21st, 2020|Hot Topics, News, Science and Research|

On December 18th, 2020, the Food and Drug Administration (FDA) approved Tagrisso (osimertinib) for the adjuvant treatment of stage IB-IIIA non-small cell lung cancer (NSCLC) that has been surgically removed, when the cancer has a change in EGFR. The [...]